ALK and non-small cell lung carcinoma: Results from a 27.8-month follow-up revealed that the use of alectinib as adjuvant therapy in completely resected stage IB to IIIA ALK-positive NSCLC patients can reduce the risk of disease recurrence or death by 76% compared to the platinum-based chemotherapy group, (hazard ratio [HR] = 0.24, 95% CI: 0.13-0.43, p <0.0001).